Navigation Links
Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
Date:3/15/2010

inical trials; reliance on third parties to manufacture, market and distribute many of our products; our ability to commercialize and market acceptance of KRYSTEXXA; difficulties in obtaining financing; potential development of alternative or more effective products by competitors; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this press release to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.

SVNT - G

SOURCE Savient Pharmaceuticals, Inc.


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
2. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
3. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
4. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
7. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Savient Provides Update on Pegloticase BLA
9. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
10. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
11. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com ... Collaborative R&D Terms & Agreements ... https://www.reportbuyer.com/product/2276220/Collaborative-RD-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html The Collaborative R&D ... Diagnostics report provides comprehensive understanding and unprecedented ... agreements entered into by the worlds leading ...
(Date:8/27/2014)... FAIRFAX, Va. , Aug. 27, 2014 ... in the legs due to buildup of fatty plaque ... expected in the aging patient population and in incidences ... Radiology offers its Lower Extremity Arterial RevascularizatioN ... Ariz. Endovascular specialists and interested residents and ...
(Date:8/27/2014)...  Decision Resources Group finds that physicians surveyed ... gastroenterology, endocrinology and nephrology) expect the robustness and ... been assessed in to be the strongest influencers ... Other key findings from the ... of Biosimilars Across Physician Specialties : ...
Breaking Medicine Technology:Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 4Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 6Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 7Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 8Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 9LEARN to Treat Peripheral Arterial Disease Patients 2LEARN to Treat Peripheral Arterial Disease Patients 3Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials 2
... CT Colonography Trial Raise Questions for,Patients, OAK ... CT Colonography Trial, published in the September 18 ... improvements in the technology,s,ability to diagnose intermediate- to ... testing is not as effective in diagnosing small ...
... September 18th New England Journal of,Medicine, Each year ... these deaths could be prevented by regular screening. Yet, ... be screened for the disease are,not being tested - ... with current screening exams., However, results of an ...
Cached Medicine Technology:ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 2ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 3ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 4ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 5MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy 2
(Date:8/27/2014)... Delta, a reliable supplier of high quality ... D7R Dozers to its used bulldozer collection. ... that all these items are offered with deep discounts. ... Delta’s market share in the coming September. , ... offer; he has much confidence in the discounted Used ...
(Date:8/27/2014)... Philadelphia, PA. Inc. magazine ranked Holganix as No. ... exclusive ranking of the nation’s fastest-growing privately held companies. ... most important segment of the economy - America’s independent ... members of the Inc. 500 list include Dell, LinkedIn, ... world’s greatest companies have had their start on the ...
(Date:8/27/2014)... Diego, CA (PRWEB) August 27, 2014 ... insurance policies will now be easier for the public ... insurance prices that are promoted in all 50 states ... . , The different insurers that are generating ... made it possible for adults to use the programmed ...
(Date:8/27/2014)... August 27, 2014 Today, Zane Benefits, ... on compliance tips for administering a premium reimbursement plan. ... in full effect, compliance is top of mind for ... to individual health insurance and premium reimbursement, there are ... In the 35 minute webinar, Zane Benefits President, Rick ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 Top 10 Best ... compared many Linux hosting suppliers and announced iPage, Bluehost and ... USA, UK, Canada, Australia and Europe to buy useful hosting ... the most reliable suppliers, iPage has been serving ... years’ development, it has grown into a leader in the ...
Breaking Medicine News(10 mins):Health News:Reliable Supplier Delta Adds New Items To Its Used Bulldozer Collection 2Health News:Inc Magazine Unveils 33rd Annual List of America's Fastest-Growing Private Companies - the Inc. 500 2Health News:Home Insurance Prices for All 50 States Now Supplied at Consumer Insurance Portal Online 2Health News:Zane Benefits Announces Upcoming Webinar on Compliance 2Health News:Well-known SEO Hosts Review Site Top10BestSEOHosting.com Recommends iPage, Bluehost and GoDaddy To Webmasters 2
... topical compound is as effective at treating the skin ... the standard therapy, a less-available, costlier compound injected into ... team from Johns Hopkins University , Harvard ... by Reza F. Ghohestani, M.D., Ph.D., director of the ...
... Receives EU and US Approvals for Intravenous Formulation of ... Sachet PresentationKENILWORTH, N.J., March 5 Schering-Plough Corporation (NYSE: ... Commission and the US FDA both approved the intravenous ... already approved oral form of the drug. Temozolomide ...
... to ExpertsBETHESDA, Md., March 5 The American College of ... the March issue of The American Journal of Gastroenterology. ... update of those published by ACG in 2000. Key ... , ...
... acquisition of NMHC drives GAAP earnings per share growth, ... up from $6.5 million in Q4, ... Corp. ("SXC" or the "Company") (NASDAQ: SXCI , TSX: ... ended December 31, 2008. Financial references are in U.S. dollars unless ...
... Anti-Doping Agency (WADA) has banned athletes from using bottled ... of the sports that it governs.LAKE FOREST, Calif., March ... Anti-Doping Agency (WADA), bottled or canned oxygen is banned ... "Artificially enhancing the uptake, transport or delivery of oxygen ...
... imaging and file conversion services available through Lifeboat,s reseller network; ... , ... Northglenn, CO (PRWEB) March ... the imaging industry, today announced a distribution agreement with Lifeboat ...
Cached Medicine News:Health News:The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 3Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 4Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 5Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 6Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 7Health News:American College of Gastroenterology Issues Updated Colorectal Cancer Guidelines 2Health News:American College of Gastroenterology Issues Updated Colorectal Cancer Guidelines 3Health News:American College of Gastroenterology Issues Updated Colorectal Cancer Guidelines 4Health News:SXC Health solutions announces strong fourth quarter and year end financial results 2Health News:SXC Health solutions announces strong fourth quarter and year end financial results 3Health News:SXC Health solutions announces strong fourth quarter and year end financial results 4Health News:SXC Health solutions announces strong fourth quarter and year end financial results 5Health News:SXC Health solutions announces strong fourth quarter and year end financial results 6Health News:SXC Health solutions announces strong fourth quarter and year end financial results 7Health News:SXC Health solutions announces strong fourth quarter and year end financial results 8Health News:SXC Health solutions announces strong fourth quarter and year end financial results 9Health News:SXC Health solutions announces strong fourth quarter and year end financial results 10Health News:SXC Health solutions announces strong fourth quarter and year end financial results 11Health News:SXC Health solutions announces strong fourth quarter and year end financial results 12Health News:SXC Health solutions announces strong fourth quarter and year end financial results 13Health News:SXC Health solutions announces strong fourth quarter and year end financial results 14Health News:SXC Health solutions announces strong fourth quarter and year end financial results 15Health News:SXC Health solutions announces strong fourth quarter and year end financial results 16Health News:SXC Health solutions announces strong fourth quarter and year end financial results 17Health News:SXC Health solutions announces strong fourth quarter and year end financial results 18Health News:SXC Health solutions announces strong fourth quarter and year end financial results 19Health News:SXC Health solutions announces strong fourth quarter and year end financial results 20Health News:Oxygen4Energy: International Sports News - World Anti-Doping Agency (WADA) Bans Oxygen Use 2Health News:Lifeboat Distribution and ImageDoc USA Sign Distribution Agreement 2
Microplate incubator shaker used in a variety of immunoassay and research procedures requiring microplates....
... especially suited for cell analysis and ... allows to analyze scatter signals in ... channels. Data acquisition, analysis, and real-time ... PC employing Partec DPAC software, built-in ...
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
... The IMMULITE 1000 immunoassay system ... use, reliability, robust hardware and excellent ... onboard reagents and accommodates onboard dilutions, ... , , Worldwide, IMMULITE 1000 (and ...
Medicine Products: